Key facts
as of Oct 2026- Developer of reactive oxygen delivery systems intended for wound care and infection control.
- Matoke Holdings is valued at approximately $26.1M as of Oct 2026 (last reported valuation).
- It has raised $17.7M; the latest was Later Stage VC ($15.7M) in Feb 2026.
- Notable investors include The BioHub Birmingham.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$26.1M
Matoke Holdings's last reported valuation, Feb 2026. Nothing priced has surfaced since.
Free account
More of Matoke Holdings with a free account
- ·Watch Matoke Holdings: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for Matoke Holdings are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
Investors
1About Matoke Holdings
Developer of reactive oxygen delivery systems intended for wound care and infection control. The company offers clinicians treating acute, surgical, and chronic wounds, to control potential and actual infections, biofilm and positively driving wound repair, providing patients with wound infection control and healing technology.
- Sector
- Healthcare
- HQ
- Southmoor, United Kingdom
- Founded
- 2010
- Employees
- 19
- Website
- matokeholdings.com/
- Ownership
- Privately Held (backing)